You are here

tislelizumab

BeiGene to go solo with cancer drug after Novartis deal termination

Yahoo/Reuters

Tue, 09/19/23 - 10:30 am

BeiGene's gastric cancer drug succeeds in late-stage trial

Reuters

Thu, 04/20/23 - 11:41 am

clinical trials

BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches

Fierce Pharma

Mon, 02/27/23 - 07:06 pm

ESMO 2022 – the new liver cancer entrants line up

EP Vantage

Thu, 09/8/22 - 10:39 am

What This FDA Delay Means for Novartis

Motley Fool

Thu, 07/21/22 - 10:36 am

FDA Indefinitely Delays BeiGene/Novartis anti-PD-1 Esophageal Cancer Drug

BioSpace

Thu, 07/14/22 - 10:51 am

esophageal cancer

Novartis, BeiGene lay out frontline PhIII data for PD-1 drug as second-line PDUFA date looms

Endpoints

Thu, 06/30/22 - 12:11 pm

gastrointestinal cancer

Novartis records another tislelizumab win en route to bringing BeiGene's PD-1 to FDA's doors

Endpoints

Wed, 04/27/22 - 10:32 am

esophageal cancer

BeiGene’s Tislelizumab Improves Survival in Esophageal Cancer Study

BioSpace

Thu, 01/28/21 - 11:10 pm

monoclonal antibodies

clinical trials

esophageal cancer

BeiGene reports positive Phase III interim analysis for lung cancer drug

MedCity News

Wed, 04/15/20 - 10:41 am

clinical trials

non-squamous non-small cell lung cancer

BeiGene lung cancer treatment meets main goal in late-stage study

Reuters

Tue, 01/21/20 - 11:53 am

clinical trials

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1

Endpoints

Wed, 11/13/19 - 10:03 am

The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)

Yahoo/Motley Fool

Fri, 06/28/19 - 10:14 am

Bristol-Myers Squibb

BeiGene Presents Encouraging Results in Ph I Trial of Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors

Thu, 09/20/18 - 09:47 am

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

CP Wire

Wed, 07/25/18 - 03:11 pm

monoclonal antibodies

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

Wed, 07/25/18 - 09:49 am

checkpoint inhibitors

Boehringer, BeiGene enter manufacturing pact for PD-1 drug

Biopharma Dive

Thu, 01/11/18 - 11:54 pm

Boehringer Ingelheim

drug manufacturing